Simcere and Stanford partner to develop IPF therapies
If the research is successful, Simcere may in-license the molecule and obtain all global rights to the product.
Drug Development
FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
FDA grants priority review for Roche’s Tecentriq combo sBLA
XtalPi enters $400m partnership for small molecule therapy for GPCR target
EMA validates Bayer’s asundexian application for ischaemic stroke
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
Aditxt and Ignite announce merger plans with strategic partner
